Studying risankizumab in children with Crohn's disease
Treatments studied
Part of Digestive system clinical trials.
This study follows children with Crohn's disease who have already started taking risankizumab. It aims to see how well the treatment works in real-world use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child is under 18 years old.
- Your child has been diagnosed with Crohn's disease.
- Your child has already started taking risankizumab (at least one dose).
- Your child can take risankizumab alone or with other Crohn's medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether risankizumab can help people with a type of Crohn's disease where the intestine becomes narrowed (fibrostenotic) and causes symptoms like cramping or vomiting. The goal is to see if the drug can reduce inflammation and improve these blockages.
This trial compares two drugs, guselkumab and risankizumab, to see which works better for people with moderate-to-severe Crohn's disease. Both are given as injections and aim to reduce inflammation in the gut.
This study keeps track of how infliximab works and how safe it is in Chinese children with moderate-to-severe active Crohn’s disease. You may be eligible if this is the first time your child is starting infliximab and you agree to provide study information.
This trial tests a drug called risankizumab (Skyrizi) for people whose Crohn's disease has led to anal fistulas that haven't improved with other treatments. The goal is to see if risankizumab can help these fistulas heal and stop draining.
This trial studies a combination of immune-suppressing treatments for children with Crohn’s disease that is not well controlled. It may help reduce inflammation and improve symptoms if you meet the study’s disease-activity and safety requirements.
This study tests a new medicine called risankizumab for children with moderate to severe Crohn's disease. It is given as an IV infusion or a shot under the skin to see if it can reduce inflammation and improve symptoms.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.